» Articles » PMID: 19196889

Assessing Glycemic Control in Maintenance Hemodialysis Patients with Type 2 Diabetes

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2009 Feb 7
PMID 19196889
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Optimizing glycemic control in diabetic patients undergoing maintenance hemodialysis requires accurate assessment. We hypothesize that 1) 48-h continuous glucose monitoring (CGM) provides additional, clinically relevant, information to that provided by the A1C measurement and 2) glycemic profiles differ significantly between day on and day off dialysis.

Research Design And Methods: With the use of GlucoDay S, 48-h CGM was performed in 19 type 2 diabetic subjects undergoing hemodialysis to capture consecutive 24-h periods on and off dialysis. Energy intake was calculated using food diaries. A1C was assayed by a high-performance liquid chromatography method.

Results: CGM data were available for 17 subjects (13 male) with a mean (range) age of 61.5 years (42-79 years) and diabetes duration of 18.8 years (4-30 years). The 24-h CGM area under the glucose curve and 24-h mean glucose values were significantly higher during the day off dialysis than on dialysis (5,932.1 +/- 2,673.6 vs. 4,694 +/- 1,988.0 mmol x 3 min(-1) x l(-1), P = 0.022, and 12.6 +/- 5.6 vs. 9.8 +/- 3.8 mmol/l, P = 0.013, respectively), independent of energy intake. Asymptomatic hypoglycemia occurred in 4 subjects, 3 within 24 h of dialysis, and the glucose nadir in 14 subjects occurred within 24 h of dialysis.

Conclusions: Glucose values are significantly lower on dialysis days than on nondialysis days despite similar energy intake. The risk of asymptomatic hypoglycemia was highest within 24 h of dialysis. Physicians caring for patients undergoing hemodialysis need to be aware of this phenomenon and consider enhanced glycemic monitoring after a hemodialysis session. CGM provides glycemic information in addition to A1C, which is potentially relevant to clinical management.

Citing Articles

Efficacy and safety of intradialytic parenteral nutrition using ENEFLUID® in malnourished patients receiving maintenance hemodialysis: An exploratory, multicenter, randomized, open-label study.

Kabasawa H, Hosojima M, Kanda E, Nagai M, Murayama T, Tani M PLoS One. 2024; 19(12):e0311671.

PMID: 39666754 PMC: 11637329. DOI: 10.1371/journal.pone.0311671.


Research Progress on the Application of CGM in Patients with Diabetes and Hemodialysis.

Huang P, He J, Ren L, Yang R, Feng D, Li L Int J Med Sci. 2024; 21(15):3083-3090.

PMID: 39628691 PMC: 11610330. DOI: 10.7150/ijms.102727.


Efficacy of continuous glucose monitoring in people living with diabetes and end stage kidney disease on dialysis: a systematic review.

Zhang Y, Singh P, Ganapathy K, Suresh V, Karamat M, Baharani J BMC Nephrol. 2024; 25(1):379.

PMID: 39455937 PMC: 11515242. DOI: 10.1186/s12882-024-03763-z.


Diabetes technology in people with diabetes and advanced chronic kidney disease.

Galindo R, Soliman D, Chernavvsky D, Rhee C Diabetologia. 2024; 67(10):2129-2142.

PMID: 39112642 PMC: 11446991. DOI: 10.1007/s00125-024-06244-y.


Continuous glucose monitoring in people with diabetes and end-stage kidney disease-review of association studies and Evidence-Based discussion.

Jakubowska Z, Malyszko J J Nephrol. 2023; 37(2):267-279.

PMID: 37989976 PMC: 11043101. DOI: 10.1007/s40620-023-01802-w.


References
1.
Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

2.
Bry L, Chen P, Sacks D . Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001; 47(2):153-63. View

3.
. Standards of medical care in diabetes--2007. Diabetes Care. 2006; 30 Suppl 1:S4-S41. DOI: 10.2337/dc07-S004. View

4.
Maran A, Crepaldi C, Tiengo A, Grassi G, Vitali E, Pagano G . Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care. 2002; 25(2):347-52. DOI: 10.2337/diacare.25.2.347. View

5.
Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View